Free tool
FAERS Monitor: Bridion
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022225 or its brand name (Bridion, Sugammadex Sodium). Reports on generic versions are filed under their own applications.
Reports
2,731
Serious
2,306
84% of reports
Hospitalization
935
Death reported
104
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic reaction315
- bradycardia285
- cardiac arrest195
- anaphylactic shock174
- bronchospasm173
- hypotension165
- drug ineffective145
- recurrence of neuromuscular blockade107
- off label use96
- oxygen saturation decreased95
- drug interaction78
- dyspnoea71
- blood pressure decreased67
- hypoxia67
- tachycardia57
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 34 |
| 2013 | 50 |
| 2014 | 35 |
| 2015 | 49 |
| 2016 | 204 |
| 2017 | 226 |
| 2018 | 286 |
| 2019 | 274 |
| 2020 | 225 |
| 2021 | 209 |
| 2022 | 217 |
| 2023 | 255 |
| 2024 | 240 |
| 2025 | 272 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,428 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| recurrence of neuromuscular blockadeSignal | 107 | 12887.4 | 9476.4 | 511,209 |
| bronchospasmSignal | 173 | 94.5 | 81.7 | 15,727 |
| anaphylactic shockSignal | 174 | 52.3 | 45.3 | 8,663 |
| anaphylactic reactionSignal | 315 | 44.2 | 39.8 | 13,201 |
| bradycardiaSignal | 285 | 41.6 | 37.3 | 11,225 |
| cardiac arrestSignal | 195 | 18.2 | 15.9 | 3,163 |
| hypoxiaSignal | 67 | 14.7 | 11.6 | 840 |
| oxygen saturation decreasedSignal | 95 | 13.0 | 10.7 | 1,045 |
| blood pressure decreasedSignal | 67 | 7.8 | 6.1 | 389 |
| hypotensionSignal | 165 | 6.3 | 5.5 | 743 |
| tachycardiaSignal | 57 | 4.9 | 3.8 | 176 |
| drug interactionSignal | 78 | 3.8 | 3.0 | 158 |
| dyspnoea | 71 | 1.0 | 0.8 | 0 |
| drug ineffective | 145 | 0.8 | 0.7 | 4 |
| off label use | 96 | 0.8 | 0.7 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.